N/A N=124 Comparison of Patient Satisfaction Using Heated Versus Room Temperature Ultrasound Gel
Ultrasound
Primary: Patient Satisfaction — 87.6; 83.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=444 Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Adherence to Supplemental O2 Prescription — 77; 73; 97 Participants
Phase 1 N=54 A Study for Participants With Advanced Cancer
Advanced Cancer · Metastatic Cancer
Primary: Recommended Dose for Phase 2 Studies — 4.0; 6.0 mg/m²/day
N/A N=898 Shared Decision Making in the Emergency Department: Chest Pain Choice Trial
Chest Pain · Acute Coronary Syndrome
Primary: Test if Chest Pain Choice Safely Improves Patient Knowledge. — 4.2; 3.6 number of questions correct
N/A N=70 An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
Hyponatremia · Syndrome of Inappropriate ADH (SIADH) Secretion
Primary: Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)…
Phase 3 N=300 A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
Coronary Heart Disease
Primary: Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment — 43.8; 10.1 Percentage raise in HDL-C Levels
Phase 1 N=15 BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Process for the Determination of the Maximum Tolerated Dose (MTD). — 0; 0; 2 Participants
N/A N=115 User Study for Enhanced Meter Feature
Diabetes Mellitus
Primary: Enhanced Meter Feature Usability — 50 Participants
Phase 1 N=16 Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Type 2 Diabetes Mellitus · Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin — 1413; 1618 ng•hr/mL
Phase 2 N=265 A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
Infertility
Primary: Number of Oocytes Retrieved — 5.2; 7.9; 9.2; 10.5 Oocytes — p=<0.001
Phase 4 N=103 Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B
Hepatitis B Vaccine
Primary: Percentage of Subjects With an Anamnestic Response to the HBV Challenge Dose, Based on the Last Available Time Point Before the Challenge Dose — 66.7; 85.3 Percentage of…
Phase 3 N=701 Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
Infections, Meningococcal
Primary: Percentages of Subjects With Human Serum Bactericidal Antibody (hSBA) Seroresponse Against Neisseria Meningitidis Serogroups A, C, W and Y. — 97.97; 97.01; 97.50; 64.71…
Phase 1 N=30 A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
Healthy
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major…
Phase 2 N=10 Dextroamphetamine and tDCS to Improve the Fluency
Stroke
Primary: Percent Change in Language Quotient as Assessed by the Western Aphasia Battery — 11.02; -4.2 percent change in language quotient — p=0.008
Phase 3 N=306 Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children
Acute Upper Respiratory Tract Infections
Primary: Percentage of Patients With Recovery/Improvement in Health on Days 2, 3 and 4 of Observation (Based on Patient Diary Data) — 9; 1; 21; 11 percentage of participants…